Cancer Research  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 10, 178-185, March 1, 1950]
© 1950 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugiura, K.
Right arrow Articles by Stock, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugiura, K.
Right arrow Articles by Stock, C. C.

The Effect of 8-Azaguanine on the Growth of Carcinoma, Sarcoma, Osteogenic Sarcoma, Lymphosarcoma and Melanoma in Animals*

Kanematsu Sugiura, Sc.D., George H. Hitchings, Ph.D., Liebe F. Cavalieri, Ph.D. and C. Chester Stock, Ph.D.

(From the Division of Experimental Chemotherapy and the Division of Protein Chemistry, the Sloan-Kettering Institute for Cancer Research, New York, N.Y., and The Wellcome Research Laboratories, Tuckahoe, N.Y.)

1. 8-azaguanine (5-amino-7-hydroxy-1H-v-triazolo [d] pyrimidine) had a definite inhibitory effect on the growth of mammary adenocarcinoma E0 771; however, it had no complete destructive action upon this tumor.
2. The inhibition was most apparent when the compound was administered early in the development of the tumor. There was little or no effect on adenocarcinoma E0 771 if treatment was delayed until 6 days after transplantation.
3. Spontaneous mammary cancers in C3H (Bar Harbor) and in Swiss mice (Rockland Farms) were apparently unaffected by repeated injections of 8-azaguanine.
4. The use of 8-azaguanine in the treatment of mice bearing Sarcoma 180, sarcoma T241, Harding-Passey melanoma, Wagner osteogenic sarcoma, or Patterson lymphosarcoma, and of rats bearing Flexner-Jobling carcinoma, Sarcoma R39, or Walker carcino-sarcoma 256, produced neither an inhibitory nor a curative effect upon these tumors.
5. Repeated intraperitoneal injections of 8-azaguanine into C57 black mice bearing adenocarcinoma E0 771 produced extensive gelatinous edema in the subcutaneous tissues and tissues of the thoracic and abdominal walls, and intraperitoneal hemorrhage and ascites. These changes were less pronounced in albino mice and were absent in albino rats.

* This work was supported from a grant by the Charles F. Kettering Foundation to the Wellcome Research Laboratories and by a grant to the Sloan-Kettering Institute from the American Cancer Society.

Received 11/28/49.


This article has been cited by other articles:


Home page
ScienceHome page
C. P. Rhoads
Rational Cancer Chemotherapy
Science, January 15, 1954; 119(3081): 77 - 80.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1950 by the American Association for Cancer Research.